Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts KYTX Hot Sheet
Join SI Premium – FREE
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) reported Q2 EPS of ($0.97), $0.05 better than the analyst estimate of ($1.02).
For earnings history and earnings-related data on Kyverna Therapeutics, Inc. (KYTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Avery Dennison (AVY) Tops Q3 EPS by 10c, Beats on Revenue; Offers FY26 EPS Guidance
- Merck (MRK) Tops Q3 EPS by 40c, Beats on Revenue; Offers FY Guidance
- Norwegian Cruise Line (NCLH) Tops Q3 EPS by 19c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
